2015 ACVIM Forum Research Abstract Program

aluate clinical outcome in idiopathic epileptic dogs administered ZON or LEV monotherapy, and compare this to dogs on phenobarbital (PB) monotherapy. Medical records from 2003-2013 were retrospectively searched for dogs diagnosed with idiopathic epilepsy administered either ZON, LEV or PB monotherapy. Information on duration of therapy, adverse effects, and outcome was collected from medical records, referring veterinarians, and owner questionnaire. A total of 121 cases were included; 16 dogs on LEV, 40 dogs on ZON, and 65 dogs on PB. Dogs in the PB group were younger at the time of the first seizure compared to the LEV and ZON groups (p = 0.05). Mean duration of therapy was similar between groups (437, 583, and 488 days for LEV, ZON, and PB, respectively). For dogs alive at the time of writing, the PB group was more likely to still be on monotherapy than the LEV or ZON groups (p = 0.04). Seizure frequency was the most common reason for monotherapy failure in all groups. The incidence of adverse effects was higher in the PB group (78%) compared to the LEV (17%) or ZON groups (36%) (p = 0.0001), although the incidence of sedation was similar. These results suggest that when compared to PB, ZNS and LEV monotherapy are associated with fewer adverse effects in dogs, although add-on therapy might be required sooner. The purpose of this retrospective study was to describe the use and efficacy of a midazolam continuous rate infusion (CRI) in dogs with cluster seizures (CS) or status epilepticus (SE).